RT Journal Article
SR Electronic
T1 Prevention of COVID-19 by mRNA-based vaccines within the general population of California
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.08.21255135
DO 10.1101/2021.04.08.21255135
A1 Kristin L. Andrejko
A1 Jake Pry
A1 Jennifer F. Myers
A1 Nicholas P. Jewell
A1 John Openshaw
A1 James Watt
A1 Seema Jain
A1 Joseph A. Lewnard
A1 on behalf of the California COVID-19 Case-Control Study Team
YR 2021
UL http://medrxiv.org/content/early/2021/05/25/2021.04.08.21255135.abstract
AB Background Estimates of COVID-19 vaccine effectiveness under real-world conditions, and understanding of barriers to uptake, are necessary to inform vaccine rollout.Methods We enrolled cases (testing positive) and controls (testing negative) from among the population whose SARS-CoV-2 molecular diagnostic test results from 24 February-29 April 2021 were reported to the California Department of Public Health. Participants were matched on age, sex, and geographic region. We assessed participants’ self-reported history of COVID-19 vaccine receipt (BNT162b2 and mRNA-1273). Participants were considered fully vaccinated two weeks after second dose receipt. Among unvaccinated participants, we assessed willingness to receive vaccination, when eligible. We measured vaccine effectiveness (VE) via the matched odds ratio of prior vaccination, comparing cases with controls.Results We enrolled 1023 eligible participants aged ≥18 years. Among 525 cases, 71 (13.5%) received BNT162b2 or mRNA-1273; 20 (3.8%) were fully vaccinated with either product. Among 498 controls, 185 (37.1%) received BNT162b2 or mRNA-1273; 86 (16.3%) were fully vaccinated with either product. Two weeks after second dose receipt, VE was 86.8% (95% confidence interval: 68.6-94.7%) and 85.6% (69.1-93.9%) for BNT162b2 and mRNA-1273, respectively. Fully vaccinated participants receiving either product experienced 91.3% (79.7-96.3%) and 68.3% (28.5-86.0%) VE against symptomatic and asymptomatic infection, respectively. Among unvaccinated participants, 42.4% (159/375) residing in rural regions and 23.8% (67/281) residing in urban regions reported hesitancy to receive COVID-19 vaccination.Conclusions Authorized mRNA vaccines are effective at reducing documented SARS-CoV-2 infections within the general population of California. Vaccine hesitancy presents a barrier to reaching coverage levels needed for herd immunity.Brief pointsVaccination is preventing documented SARS-CoV-2 infection in California, with 68% and 91% effectiveness against asymptomatic and symptomatic infection, respectively.Vaccine effectiveness was equivalent for BNT126b2 and mRNA-1273.Only 66% of unvaccinated participants were willing to receive the vaccine when eligible.Competing Interest StatementJAL discloses receipt of grants and honoraria from Pfizer, Inc. unrelated to this work.Funding StatementThe study was supported by the California Department of Public Health. JP, JO, and JFM were supported by a grant from the ELC program of the US CDC (program number 0187.0150). JAL and NPJ were supported by NIH/NIAID (grant R01-AI14812701).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was granted a non-research determination by the State of California Health and Human Services Agency Committee for the Protection of Human Subjects (project number: 2021-034).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data should be communicated to the California Department of Public Health.